4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Fátima Cardoso(Breast Cancer Alliance), E.P. Winer(Dana-Farber Cancer Institute), Fabrice André(Inserm), Gertrude Nakigudde(Uganda Cancer Institute), Giuseppe Curigliano(European Institute of Oncology), S. Johnston(Royal Marsden NHS Foundation Trust), A. Costa(European School of Oncology), Smruti Koppikar(Lilavati Hospital & Research Centre), Danielle Spence(Breast Cancer Network Australia), D.A. Vorobiof, Efthymios Papadopoulos(Louisiana State University), B.V. Offersen(Aarhus University Hospital), Nadia Harbeck(Breast Center), Matti Aapro(Clinique de Genolier), B. Aguilar Lopez(Universidad Latinoamericana), B. Xu(Henan University of Traditional Chinese Medicine), Maria João Cardoso(Champalimaud Foundation), Larry Norton(Memorial Sloan Kettering Cancer Center), P.A. Francis(Peter MacCallum Cancer Centre), I.E. Krop(Dana-Farber Cancer Institute), Nagi S. El Saghir(American University of Beirut Medical Center), Bella Kaufman(NYU Langone Health), Laura Biganzoli(Hospital of Prato), Javier Cortés(Villa Maria Hospital), Véronique Dièras(Institut Curie), Shinji Ohno(Unknown), Elżbieta Senkus(Gdańsk Medical University), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Frédérique Penault‐Llorca(Inserm), L.A. Carey(University of North Carolina Health Care), Karen A. Gelmon(University of British Columbia), Olivia Pagani(Swiss Group For Clinical Cancer Research), Jonas Bergh(Karolinska Institutet), H.S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center), Lesley Fallowfield(Brighton and Sussex Medical School), C.B. Boers-Doets, Aleix Prat(Hospital Clínic de Barcelona), Musa Mayer, G. W. Sledge(Stanford Medicine), Shani Paluch–Shimon(Hebrew University of Jerusalem), C.H. Barrios, Christoph Thomssen(Martin Luther University Halle-Wittenberg)
Cited by 1,189
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k